T
4.62
-0.15 (-3.14%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | TuHURA Biosciences, Inc. | 看跌 | - |
AIStockmoo 评分
-0.6
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -0.63 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 41.96% |
| 机构持股比例 | 8.43% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cyndeo Wealth Partners, Llc | 31 Dec 2024 | 10,627 |
| 52周波幅 | ||
| 中 | 12.00 (159.74%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 May 2025 | 12.00 (159.74%) | 购买 | 3.92 |
| 03 Apr 2025 | 12.00 (159.74%) | 购买 | 3.40 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合